Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

Brought to you by

Cell Genesys acquires fellow gene therapy co. Somatix

Executive Summary

Cell Genesys acquired Somatix Therapy by exchanging 0.385 shares for each of Somatix's 24.4mm outstanding shares (about $3.40 per share, based on Cell Genesys' closing price the day of the deal's announcement) in a deal worth about $82.7mm.
Deal Industry
  • Biotechnology
    • Gene Therapy, Cell Therapy
    • Large Molecule
  • Pharmaceuticals
Deal Status
  • Final
Deal Type
  • Acquisition
    • Full Acquisition
    • Payment Includes Stock

Related Companies